INmune Bio, Inc. cash flow to debt ratio of -2.18K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

INmune Bio, Inc.'s free cash flow has increased -29.19% from $-33.36M last year to $-23.62M, signaling increasing performance

INmune Bio, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

INmune Bio, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.07 today, signaling weakened financials

INmune Bio, Inc. has a net cash position, so leverage is healthy.

INmune Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

INmune Bio, Inc.'s profit margin has increased (-100.00%) in the last year from -300.59K% to 0.00%, signaling increasing performance

INmune Bio, Inc.'s short-term assets of $29.89M exceed its short-term liabilities of $8.42M

INmune Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

INmune Bio, Inc.'s return on equity of -82.87%, is lower than 15.00%, indicating bad performance

INmune Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

INmune Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

INmune Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

INmune Bio, Inc. has negative free cash flow, indicating cash burn

INmune Bio, Inc.'s yearly earnings has decreased 9.15% since last year from $-42.08M to $-45.93M, signaling decreasing performance

INmune Bio, Inc.'s yearly revenue has increased 257.14% since last year from $14.00K to $50.00K, signaling increasing performance

ROIC -92.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

INmune Bio, Inc.'s 3-year revenue CAGR of -48.87% is negative, indicating declining revenue over the past 3 years

INmune Bio, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

INmune Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

INmune Bio, Inc. has insufficient data to evaluate this check.

INmune Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

INmune Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

INmune Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

INmune Bio, Inc. has insufficient data to evaluate this check.

INmune Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

INmune Bio, Inc. has a price-to-book ratio of 2.78x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

INmune Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue